Inhaled Tacrolimus, Add-on to Inhaled Corticosteroids & Long Acting B2 Agonists in Moderate to Severe Persistent Asthma
Phase 2
Completed
- Conditions
- Asthma, BronchialBronchial Asthma
- Registration Number
- NCT00189722
- Lead Sponsor
- Astellas Pharma Inc
- Brief Summary
This study will evaluate the efficacy and safety of tacrolimus in patients with asthma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
- Diagnosis of asthma
- Patients treated with inhaled corticosteroid and long acting beta 2 agonist
- FEV1(forced expiratory volume in 1 second)>50% to 80%
Exclusion Criteria
- Respiratory infection within 2weeks
- Asthma exacerbation within 6 weeks
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method